These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 12484508

  • 1. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [Abstract] [Full Text] [Related]

  • 2. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S, Tomonari H, Ohtsuka Y, Ohkido I, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2003 Nov; 45(4):367-71. PubMed ID: 12806973
    [Abstract] [Full Text] [Related]

  • 3. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 4. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 6. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov 09; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R, Tonolo G.
    J Am Soc Nephrol; 2002 Nov 09; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [Abstract] [Full Text] [Related]

  • 8. [A clinical evaluation on the combination therapy with ACE-I and ARB, and with ARB and CCB in patients with progressive chronic renal diseases].
    Kuriyama S.
    Nihon Rinsho; 2002 Oct 09; 60(10):2014-9. PubMed ID: 12397700
    [Abstract] [Full Text] [Related]

  • 9. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.
    J Hum Hypertens; 2012 Apr 09; 26(4):214-9. PubMed ID: 21412266
    [Abstract] [Full Text] [Related]

  • 10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 09; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 11. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

  • 12. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O, Laroche P, Vidal JS, Pannier B, Postel-Vinay N, Vaisse B, Girerd X.
    Ann Cardiol Angeiol (Paris); 2012 Jun 30; 61(3):218-23. PubMed ID: 22695025
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.
    Ann Intern Med; 2003 Apr 01; 138(7):542-9. PubMed ID: 12667024
    [Abstract] [Full Text] [Related]

  • 14. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec 01; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 01; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 16. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul 01; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 17. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ, Hunsicker LG, Rodby RA, Collaborative Study Group.
    Am J Kidney Dis; 2001 Oct 01; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic management of diabetic nephropathy.
    Vivian EM, Rubinstein GB.
    Clin Ther; 2002 Nov 01; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.
    Clin Exp Hypertens; 2012 Nov 01; 34(4):249-57. PubMed ID: 22571446
    [Abstract] [Full Text] [Related]

  • 20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 01; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.